Voro and Alloy Partner on Next-Gen T-Cell Cancer Therapies
SAN DIEGO, Calif. and BOSTON, Mass., June 20, 2026 Voro Therapeutics and Alloy Therapeutics have announced a strategic research...
AI drug discovery artificial intelligence Autoimmune Disease biologics Biomarkers biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy Healthcare Innovation healthcare technology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurodegenerative Disease Neurology Oncology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
SAN DIEGO, Calif. and BOSTON, Mass., June 20, 2026 Voro Therapeutics and Alloy Therapeutics have announced a strategic research...
SAN DIEGO, CA, March 17, 2026 Voro Therapeutics has announced a research collaboration with Daiichi Sankyo to advance its...
